Calliditas Therapeutics
targets the presumed origin of disease | Calliditas Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
June 2020
Slide
10 of 38
Related slides by other companies
BenevolentAI
SPAC
December 2021
successful collaboration with year target collaboration to novel targets for chronic kidney disease and idiopathic pulmonary fibrosis separate data environment established to integrate data into a bespoke knowledge graph and teams working in close collaboration to explore identify and validate targets key milestone reached took novel generated target for into their drug portfolio with further targets to follow deal structure of license fee milestone payments and downstream royalties the vast amount of data available to research scientists is growing exponentially each year by combining disease area and large diverse with leading and machine learning capabilities we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets that could treat debilitating diseases president collaboration video pos | BenevolentAI
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights